ES01.01 Chemotherapy Is Strictly Additive To Immunotherapy

The document discussed the additive effects of combining chemotherapy with immune checkpoint inhibitors (ICI) in treating advanced non-small cell lung cancer (NSCLC). It highlighted that while chemotherapy and ICI have distinct adverse event profiles, their combination did not significantly increase overall adverse events compared to chemotherapy alone. Trials like Keynote-189 and IMpower-133 showed that the combination improved response rates, progression-free survival, and overall survival. However, there was no definitive evidence favoring concurrent over sequential administration of chemo+ICI, and further research was needed to determine the optimal strategy.